T cells play a huge role in our immune system’s fight against modified cells in the body that can develop into cancer. Phagocytes and B cells identify changes in these cells and activate the T cells, which then start a full-blown program of destruction. This functions well in many cases – unless the cancer cells mutate and develop a kind of camouflage that let them escape the immune system undetected. Researchers at the University of Freiburg and the Leibniz University Hannover (LUH) have now described how a key protein in this process known as "immune escape" becomes activated.
The team headed by Prof. Dr. Maja Banks-Köhn and Prof. Dr. Wolfgang Schamel from the excellence clusters for biological signaling studies CIBSS and BIOSS at the University of Freiburg and the structural biologist Prof. Dr. Teresa Carlomagno from the LUH used biophysical, biochemical, and immunological methods in their research.
Based on these insights, chemical biologist Banks-Köhn, hopes to develop drugs that intervene specifically in this activation mechanism. In the future, they could thereby improve established cancer treatments that rely on so-called immune checkpoint inhibitors. The team has recently published its research in a study in the scientific journal "Science Advances".
Checkpoint inhibitors are therapeutic antibodies that work by binding to the receptors of T cells. Proteins on the surface of the T cells called immune checkpoint receptors such as programmed cell death 1, or PD1, along with the signaling pathways that are triggered by them are what stop immune responses in a healthy body.
This regulating mechanism prevents symptoms of inflammation from lasting too long and getting out of control. These symptoms include redness, swelling, and fever. Cancer cells take advantage of mechanisms such as these to render the body helpless while the cells multiply.
Using cell cultures and interaction studies, the researchers from the two universities discovered that a signaling protein called SHP2 in T cells binds to PD1 in two specific places after it has been activated by a signal from cancer cells. It is this double binding to SHP2 that promotes the camouflaging effect and switches off the immune cells’ response completely.
Antibodies that block immune inhibitors like PD1 are approved treatments for skin melanomas and lung carcinomas, and they prolong patients' lives. However, as a result, many patients suffer from autoimmune reactions.
“Drugs that prevent the binding of SHP2 and PD1 could be used in the future to make side-effects less severe and to support, or to act as alternatives to, antibody treatments,” says Banks-Köhn. She and Schamel studied the immune response of B cells and T cells by modifying SHP2 molecules, testing their predictions based crystal structure and magnetic resonance analysis of the team from the LUH.
Their data shows precisely how and in what areas the SHP2 protein binds to PD1, thereby revealing a possible target area for drugs. “In our ongoing research project at the CIBSS – Centre for Integrative Biological Signalling Studies the next step is to decode the signaling pathway of PD1 – in other words, where the proteins are located in the cell, where they bind, and within what time frame the signals take effect," Banks-Köhn says.
Cancer cells become invisible to the body's immune response. Unhindered by T cells (green), they can continue to replicate. Scientists have now described an important step in this process called “immune escape”. Illustration: CIBSS/University of Freiburg, Michal Rössler
Prof. Dr. Maja Banks-Köhn
Institute of Biology III / Excellence Clusters in Biological Signaling Studies CIBSS and BIOSS
Phone: +49 (0)761 / 203–67900
Marasco, M./Berteotti, A./Weyershaeuser, J./Thorausch, N./Sikorska. J./Krausze, J./Brandt, H. J./Kirkpatrick, J./Rios, P./Schamel, W. W./Köhn, M./Carlomagno, T. (2020): Molecular mechanism of SHP2 activation by PD-1 stimulation. In: Science Advances 2020/6: eaay4458.
Nicolas Scherger | idw - Informationsdienst Wissenschaft
A new view of microscopic interactions
02.07.2020 | University of Missouri-Columbia
02.07.2020 | Max Delbrück Center for Molecular Medicine in the Helmholtz Association
A promising operating mode for the plasma of a future power plant has been developed at the ASDEX Upgrade fusion device at Max Planck Institute for Plasma...
Live event – July 1, 2020 - 11:00 to 11:45 (CET)
"Automation in Aerospace Industry @ Fraunhofer IFAM"
The Fraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM l Stade is presenting its forward-looking R&D portfolio for the first time at...
With an X-ray experiment at the European Synchrotron ESRF in Grenoble (France), Empa researchers were able to demonstrate how well their real-time acoustic monitoring of laser weld seams works. With almost 90 percent reliability, they detected the formation of unwanted pores that impair the quality of weld seams. Thanks to a special evaluation method based on artificial intelligence (AI), the detection process is completed in just 70 milliseconds.
Laser welding is a process suitable for joining metals and thermoplastics. It has become particularly well established in highly automated production, for...
A research team from the Max Planck Institute for the Structure of Dynamics (MPSD) and the University of Oxford has managed to drive a prototypical antiferromagnet into a new magnetic state using terahertz frequency light. Their groundbreaking method produced an effect orders of magnitude larger than previously achieved, and on ultrafast time scales. The team’s work has just been published in Nature Physics.
Magnetic materials have been a mainstay in computing technology due to their ability to permanently store information in their magnetic state. Current...
The Venus flytrap (Dionaea muscipula) takes only 100 milliseconds to trap its prey. Once their leaves, which have been transformed into snap traps, have...
02.07.2020 | Event News
19.05.2020 | Event News
07.04.2020 | Event News
02.07.2020 | Event News
02.07.2020 | Life Sciences
02.07.2020 | Life Sciences